p53 In noncancerous bladder mucosa as a marker of disease recurrence in patients with superficial transitional cell carcinoma of the bladder

Urologic Oncology

Volumn 3, Issue 4, 1997, Pages 125-131

  Friedrich, Martin G ^a   Schwaibold, Hartwig ^a   Wintzer, Olof ^b   Pichlmeier, Uwe ^a   Huland, Hartwig ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bladder cancer; Noncancerous mucosa; p53; Recurrence

Indexed keywords

BIOCHEMICAL MARKER; GENE PRODUCT; PEROXIDASE; PROTEIN P53; STREPTAVIDIN;

ANTIGEN EXPRESSION; ARTICLE; BLADDER CARCINOMA; BLADDER MUCOSA; CANCER STAGING; CELL SURVIVAL; GENE MAPPING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; TISSUE SECTION; TRANSITIONAL CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR RECURRENCE;

EID: 0031709217     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(98)00018-0     Document Type: Article

References (31)

1. Henke R.-P., Krueger E., Ayhan N., Hübner D., Hammerer P., Huland H. Immunohistochemical detection of p53 protein in human prostatic cancer. J Urol. 152:1994;1297-1301.
2. Esrig D., Spruck C.H. III, Nichols P.W., et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer. Am J Pathol. 143:1993;1389-1397.
3. Simoneau A.R., Jones P.A. Bladder cancer The molecular progression to invasive disease . World J Urol. 12:1994;89-95.
4. Sarkis A., Dalbagni G., Cordon-Cardo C., et al. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol. 152:1994;388-392.
5. Cote R.J., Esrig D., Groshen S., Jones P.A., Skinner D.G. p53 and treatment of bladder cancer. Nature. 385:1997;123-125.
6. Serth J., Kuczyk M., Bokemeyer C., et al. p53-Immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer. 71:1995;201-205.
7. Sarkis A.S., Dalbagni G., Cordon-Cardo C., et al. Nuclear overexpression of p53 protein in transitional cell carcinoma of the bladder A marker for disease progression? J Natl Cancer Inst. 85:1993;53-59.
8. Burkhard F., Markwalder R., Thalmann G.N., Studer U.E. Immunhistochemischer Nachweis des Tumorsuppressorgens p53 als prognostischer Faktor bei oberflächlichen Blasentumoren. Urologe (A). 35:(suppl 1):1996;58.
9. Gasser Th C., Sauter G., Moch H., Mihatsch M.J. p53, Chromosom 17 Veränderungen und Prognose beim oberflächlichen Blasenkarzinom. Urologe (A). 35:(suppl 1):1996;58.
10. Jahnson S., Risberg B., Karlsson M.G., Westman G., Bergström R., Pedersen J. p53 and Rb immunostaining in locally advanced bladder cancer Relation to prognostic variables and predictive value for the local response to radical radiotherapy . Eur Urol. 28:1995;135-142.
11. Althausen A.F., Prout G.R. Jr, Daly J.J. Non invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol. 116:1976;575-580.
12. Harris A.L., Neal D.E. Bladder cancer-field versus clonal origin. N Engl J Med. 326:1992;759-761.
13. Lutzeyer W., Ruebben H., Dahm H. Prognostic parameters in superficial bladder cancer An analysis of 315 cases . J Urol. 127:1982;250-252.
14. Barnes R., Hadley H., Dick A., Johnston O., Dexter J. Changes in grade and stage of recurrent bladder tumors. J Urol. 118:1977;177-178.
15. Norming U., Tribukait B., Nyman C.R. Prognostic significance of mucosal aneuploidy in stage Ta/T1 grade 3 carcinoma of the bladder. J Urol. 148:1992;1420-1426.
16. Heinzer H., Huland E., Mönk M., Huland H. Distribution of 486p 3/12 antigen, ABO(H) blood group antigen and T antigen in cystectomy specimens from patients with stage T2 transitional cell carcinoma of the bladder. J Urol. 148:1992;802-805.
17. Lee E., Schwaibold H., Fradet Y., Huland E., Huland H. Tumor associated antigens in normal mucosa of patients with superficial transitional cell cancer of the bladder. J Urol. 157:1997;1070-1073.
18. Soini Y., Turpeenniemi-Hujanen T., Kamel D., et al. p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br J Cancer. 68:1993;1029-1035.
19. Hermanek P, Sobin KH. TNM Classification of Malignant Tumours, 4th ed., 2nd revision. Berlin: Springer Verlag, 1992.
20. Shi S.R., Key M.E., Kalra K.L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections . J Histochem Cytochem. 39:1991;741-748.
21. Schmitz-Dräger B.J., van Roeyen C.R.C., Grimm M.O., et al. p53 accumulation in precursor lesions and early stages of bladder cancer. World J Urol. 12:1994;79-83.
22. Rao J.Y., Hemstreet G.P. III, Hurst R.E., et al. Alterations in phenotypic biological markers in bladder epithelium during tumorigenesis. Proc Natl Acad Sci USA. 90:1993;8287-8291.
23. Resnick J.M., Cherwitz D., Knapp D., Uhlmann D., Niehans D.A. A microwave method that enhances detection of aberrant p53 expression in formalin-fixed, paraffin-embedded tissues. Arch Pathol Lab Med. 119:1995;360-366.
24. Vogelstein B., Kinzler K.W. p53 function and dysfunction. Cell. 70:1992;523-526.
25. Hall P.A., Lane D.P. p53 in tumor pathology: Can we trust immunohistochemistry? - revisited. J Pathol. 172:1994;1-4.
26. Cordon-Cardo C., Dalbagni G., Saez G.T., et al. p53 mutations in human bladder cancer Genotypic versus phenotypic patterns . Int J Cancer. 56:1994;347-353.
27. Kuczyk M.A., Serth J., Hervatin C., et al. Detection of p53 tumor-suppressor-gene protein in bladder tumors and prostate cancer Possible clinical implications . World J Urol. 12:1994;345-351.
28. Wagner U., Sauter G., Moch H., et al. Patterns of p53, erbV-2, and EGF-r expression in premalignant lesions of the urinary bladder. Human Pathol. 26:1995;970-978.
29. Barnes D.M., Hanby A.M., Gillett C.E., et al. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet. 340:1992;259-263.
30. 60Co irradiation. Radiat Res. 137:1994;317-322.
31. Harney J., Murphy D.M., Jones M., Mothersill C. Expression of p53 in urothelial cell cultures from tumor-bearing and tumor-free patients. Br J Cancer. 71:1995;25-29.